Tag: Novartis
Novartis: Investment projects in biotherapies
(CercleFinance.com) – Novartis announced on Tuesday that it will invest $300 million to increase its capabilities in the field of next-generation biotherapeutic drugs. The Swiss laboratory specifies that its investment…
Weko opens proceedings against Novartis
Competition authorities open proceedings against Novartis Weko examined Novartis premises. Arnd Wiegmann / Reuters tsf. The Competition Commission (Comco) has opened an investigation into a Swiss pharmaceutical company. Weko did…
Possible patent infringement – Competition Commission opens investigation against Novartis – News
Possible patent offense – Competition Commission opens investigation against Novartis – News – SRF Skip to content News Business Current article contents The Competition Commission (Comco) has opened an investigation…
Novartis: Positive Data in Hidradenitis Suppurativa
Receive the value of the day selected by The data collected is essential for this processing and is intended for the relevant departments of BFM Bourse and, where applicable, its…
Novartis: positive data in hidradenitis suppurativa
(CercleFinance.com) – During a last-minute presentation at the 31st Congress of the European Academy of Dermatology and Venereology (EADV), Novartis announces positive results from two pivotal phase III studies (SUNSHINE…
Novartis: The EU has approved a treatment for leukemia
Receive the value of the day selected by The data collected is essential for this processing and is intended for the relevant departments of BFM Bourse and, where applicable, its…
Novartis will put Sandoz on the stock market and “it makes sense”
Subscribe for 1€ Unlimited access to all advice More than 800 stocks listed in Paris and abroad screened. To buy ? Sale ? What course objective? Our experts engage and…
Novartis: Oddo remains positive with the Sandoz spin-off
Receive the value of the day selected by The data collected is essential for this processing and is intended for the relevant departments of BFM Bourse and, where applicable, its…
Novartis refocuses on innovative medicines
The Swiss pharmaceutical giant will IPO Sandoz, its generics subsidiary. Sandoz, the generic drugs subsidiary of Novartis will soon be on its own. The Swiss pharmaceutical giant announced Thursday its…
Novartis chooses the Swiss Stock Exchange to withdraw from Sandoz
Zurich (awp) – Novartis has made its decision on the future of Sandoz, having received no firm takeover offer for a subsidiary put on the balance last October. The generics…
Generics subsidiary – Novartis separates from Sandoz – News
The Basel pharmaceutical company Novartis separates from Sandoz. The generics manufacturer is to become an independent company. The company’s headquarters will remain in Switzerland. According to Novartis, the transaction should…
Novartis spins off Sandoz
Last fall, Novartis announced that it would examine “all options” for Sandoz. Now the generics division is to be listed as an independent company on the Swiss stock exchange. The…